Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) General Information

Description

A drug used for the treatment of hepatic veno-occlusive disease. The asset is used for the treatment of severe hepatic veno-occlusive disease which is an early complication in patients undertaking hematopoietic stem cell transplantation therapy.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Devices and Supplies
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Primary Office
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)‘s full profile, request access.

Request a free trial

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)‘s full profile, request access.

Request a free trial